Atopic dermatitis is the most common type of eczema affecting 5% of the population. It affects the upper layer of the skin and typically appears in early childhood. For some patients, it clears up before adulthood, while others have the condition throughout their life. Symptoms for atopic dermatitis are itchy rash, inflammation, and dry skin, and is currently diagnosed by a physical examination and medical history. Upon diagnosis, moisturizers or topical steroids are often used as the first-line of treatment for mild cases, while severe cases may receive biologicals and oral treatments.

There is a need for biomarkers in atopic dermatitis to improve diagnosis, determine disease severity, predict atopic dermatitis development, and track therapeutic response. All of this will lead to improvement of patient management and reduce clinical trial size and length when developing new efficacious treatments.

Visit our dermatology biomarker portfolio and choose a panel that fits your clinical research or drug development targets!

Atopic dermatitis is characterized as a dermatological disease where the tissue architecture is being remodeled. The main component of the skin are collagens, which are remodeled as a part of the normal homeostasis of the skin. In Atopic dermatitis, there is an imbalance of tissue build-up and tissue break down, resulting in a net degradation of the tissue. Protein fingerprint biomarkers can quantify skin tissue turnover directly in a serum sample and serve as a liquid biopsy.

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.